Department of Ophthalmology, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Department of Chemistry, Centre for Analysis and Synthesis, Lund University, Lund, Sweden.
Immunology. 2018 Jul;154(3):490-499. doi: 10.1111/imm.12899. Epub 2018 Feb 15.
Interleukin-1β (IL-1β) is a potent mediator of innate immunity commonly up-regulated in a broad spectrum of inflammatory diseases. When bound to its cell surface receptor, IL-1β initiates a signalling cascade that cooperatively induces the expression of canonical IL-1 target genes such as IL-8 and IL-6. Here, we present galectin-3 as a novel regulator of IL-1β responses in corneal keratinocytes. Using the SNAP-tag system and digitonin semi-permeabilization, we show that recombinant exogenous galectin-3 binds to the plasma membrane of keratinocytes and is internalized into cytoplasmic compartments. We find that exogenous galectin-3, but not a dominant negative inhibitor of galectin-3 polymerization lacking the N-terminal domain, exacerbates the response to IL-1β by stimulating the secretion of inflammatory cytokines. The activity of galectin-3 could be reduced by a novel d-galactopyranoside derivative targeting the conserved galactoside-binding site of galectins and did not involve interaction with IL-1 receptor 1 or the induction of endogenous IL-1β. Consistent with these observations, we demonstrate that small interfering RNA-mediated suppression of endogenous galectin-3 expression is sufficient to impair the IL-1β-induced secretion of IL-8 and IL-6 in a p38 mitogen-activated protein kinase-independent manner. Collectively, our findings provide a novel role for galectin-3 as an amplifier of IL-1β responses during epithelial inflammation through an as yet unidentified mechanism.
白细胞介素-1β(IL-1β)是先天免疫的有效介质,在广泛的炎症性疾病中普遍上调。当与细胞表面受体结合时,IL-1β启动信号级联反应,协同诱导经典的 IL-1 靶基因(如 IL-8 和 IL-6)的表达。在这里,我们将半乳糖凝集素-3 作为角膜角质形成细胞中 IL-1β反应的新型调节剂。我们使用 SNAP 标记系统和二辛可宁半透化法,表明重组外源半乳糖凝集素-3 与角质形成细胞的质膜结合,并被内化到细胞质隔室中。我们发现,外源半乳糖凝集素-3 而非缺乏 N 端结构域的半乳糖凝集素-3 聚合的显性负抑制剂,通过刺激炎症细胞因子的分泌,加剧了对 IL-1β的反应。新型 d-半乳糖吡喃糖苷衍生物可靶向半乳糖凝集素的保守半乳糖结合位点,从而降低半乳糖凝集素-3 的活性,而不涉及与 IL-1 受体 1 的相互作用或内源性 IL-1β的诱导。与这些观察结果一致,我们证明小干扰 RNA 介导的内源性半乳糖凝集素-3 表达的抑制足以在 p38 丝裂原活化蛋白激酶非依赖性方式损害 IL-1β诱导的 IL-8 和 IL-6 的分泌。总之,我们的发现为半乳糖凝集素-3 通过一种尚未确定的机制作为上皮炎症中 IL-1β反应的放大器提供了新的作用。